Comparing nebulized and intravenous hypertonic saline for treating acute respiratory distress syndrome
Comparative Study Between the Effect of Nebulized and Intravenous Hypertonic Saline 3% on the Management of Patients With Acute Respiratory Distress Syndrome
This study is testing whether breathing in or getting through an IV a special salt solution can help adults with mild to moderate acute respiratory distress syndrome breathe better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 105 (estimated) |
| Ages | 21 Years to 60 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Tanta, El-Gharbia) |
| Trial ID | NCT06226402 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of nebulized versus intravenous administration of 3% hypertonic saline in patients suffering from acute respiratory distress syndrome (ARDS). ARDS is a severe condition characterized by significant respiratory failure and inflammation in the lungs, often requiring intensive care. The study will involve patients aged 21 to 60 with mild to moderate ARDS, assessing the impact of hypertonic saline on their respiratory outcomes. The research seeks to provide insights into alternative treatment options for this life-threatening condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 21 to 60 with mild to moderate ARDS and a PaO2/FiO2 ratio of 150 or higher.
Not a fit: Patients with severe ARDS, malignancies, or significant comorbidities such as decompensated renal, hepatic, or cardiac disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a new therapeutic approach to improve outcomes for patients with acute respiratory distress syndrome.
How similar studies have performed: While the use of hypertonic saline has been explored in various contexts, this specific comparison of nebulized versus intravenous administration in ARDS is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age from 21 to 60 years old. * Both sexes. * Patients with mild and moderate ARDS whose PaO2/FiO2 ratio ≥ 150 according to the Berlin definition of Acute Respiratory Distress Syndrome. Exclusion Criteria: * Refusal to participate in the study. * Malignancy. * Patients on chemotherapy. * Decompensated renal, hepatic and cardiac disease. * Patients with hypernatremia whose serum Na above 155 mEq/L. * Patients with ARDS whose PaO2/FiO2 ratio \> 150.
Where this trial is running
Tanta, El-Gharbia
- Tanta University — Tanta, El-Gharbia, Egypt (Recruiting)
Study contacts
- Study coordinator: Mohamed E Elfakhrany, MBBCH
- Email: mohamed169729_pg@med.tanta.edu.eg
- Phone: 00201023825321
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.